Forgot Password?
Return to Course Listing

CME: Scratching the itch: Addressing unmet needs and updates in the pharmacotherapeutic management of atopic dermatitis (AD)

Activity Description / Statement of Need:

In this online, self-learning activity:

Atopic dermatitis (AD) is a chronic, highly pruritic inflammatory skin disease that is one of the most common skin disorders in children but may develop at any age. It affects 15-30% of children and two to ten percent of adults in developed countries, and between 10-30% of children who have the condition continue to experience it in adulthood. AD is thought to arise from a complicated interplay between multiple genes and environmental triggers, with known risk factors including family history and loss of function mutations in filaggrin. Complications include food allergy, asthma, and allergic rhinitis, and aside from genetics, its pathophysiology involves T-cell mediated inflammation and epidermal dysfunction. The disease is associated with a considerable healthcare burden placed on patients and their families; pruritis aside, patients not uncommonly suffer a loss of sleep and experience secondary infections, anxiety, and depression.

Target Audience:

The following HCPs: Pediatric and adult dermatologists, allergists, and internists; physician assistants, nurse practitioners, and pharmacists who treat patients with dermatologic conditions; and any other HCPs with an interest in or who diagnose, treat, or manage patients with AD.

Commercial Support Disclosure: This program is supported by an educational grant from Incyte.

This activity is free of charge.

Release Date: September 16, 2022 -- Expiration Date: September 16, 2024

Faculty: Jonathan Tam, MD


Faculty introduction, disclosures

Introduction content: cursory refresher and review of AD

  • Epidemiology: Statistics by severity
  • Healthcare burden
  • Pathophysiology with emphasis on present and investigational therapeutic targets
  • Diagnostic challenges, including overlapping dermatologic conditions and differences in patient vs. HCP ratings of severity

Treatment of AD

· Goals of care

  • Pharmacotherapy, clinical trial findings, and guideline-recommended care aimed at reducing disease burden: What works and what doesn’t
    • Mild & moderate disease: proactive versus reactive treatment; topical glucocorticoids and calcineurin, PDE-4, and JAK inhibition
    • Severe or persistent disease: Systemic therapies targeting IL-4, IL-13, & JAK; role of oral glucocorticoids and non-targeted immunosuppressants
  • Emerging and future therapies
    • Additional agents targeting IL-13, PDE-4, or JAK
    • IL-31 inhibition
    • Sphingosine 1 phosphate receptor modulation
    • Aryl hydrocarbon receptor modulation
  • Pediatric, adolescent, and adult populations
  • Questions, controversies, considerations, and challenges
    • Refractory cases
    • Duration of systemic therapy
    • Special populations
      • Atopic comorbidities (e.g., eosinophilic esophagitis, asthma, nasal polyps, complex atopic eye disease)
      • Pregnant or lactating women
      • History of severe herpes virus infections or malignancy
      • Individuals undergoing vaccination
    • Pandemic considerations
    • Managing the transitions childhood, adolescence, and adulthood
    • Roles of referral and interdisciplinary care
    • Optimizing a patient’s adherence to therapy
  • Patient cases

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the healthcare burden unique to patients with AD and challenges to optimal management.
  • Recall the impact of present and emerging pharmacotherapies for AD and the role of different treatment strategies by severity, age, and other patient characteristics.
  • Formulate a treatment plan for a patient with AD.


ACCME Activity #202336694

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-22-055-H01-P. This is an Knowledge (K)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Jonathan Tam, MD, FAAAAI, FACAAI, Associate Professor of Pediatrics, Keck School of Medicine, University of Southern California, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Incyte.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Identification and management moderate-to-severe psoriatic arthritis: stopping the disease in its tracks and meeting unmet needs

Updates in psoriasis management: Contemporary practice and novel therapies

How implicit bias and culture competence shape the patient healthcare experience